News

Insilico Medicine and Luoxin Pharma enter AI drug discovery collaboration for metabolic and digestive diseases

What's the deal? Insilico Medicine has signed a preliminary strategic cooperation agreement with Luoxin Pharmaceuticals, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange, to run AI-powered drug discovery for digestive, metabolic and other chronic diseases. Announced via HKEX on 17 November 2026 (agreement signed 13 November), the deal covers target identification, molecule discovery and optimisation, support for existing pipeline programmes and translational research. Financial terms were not disclosed and definitive agreements are still to be executed.

Why it matters: The agreement is the latest in a series of 2026 partnerships in which pharma companies license Insilico's Pharma.AI platform, following deals with Lilly (up to $2.75B), Qilu Pharmaceutical and Servier. For Luoxin it provides AI-driven molecule design for non-oncology chronic diseases; for Insilico it extends the platform's reach in China's cardiometabolic and digestive therapeutic areas.

Read more: AllSci, 17 November 2026

More top stories